Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Feb 2016

De Iuliis Francesca, Salerno Gerardo, Giuffrida Anna, Milana Bernardina, Taglieri Ludovica, Rubinacci Giovanna, Giantulli Sabrina, Terella Federica, Silvestri Ida, Scarpa Susanna

Abstract excerpt

Breast cancer is characterized by molecular heterogeneity, and four major breast cancer subtypes have been identified, each characterized by significant differences in survival, prognosis, and response to therapy. We have studied the effects of docetaxel treatment on apoptosis and survivin expression in four breast cancer cell lines: MCF7 (luminal A: estrogen receptor-positive and progesterone receptor-positive,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged-Ring Compounds
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to MCF-7 Cells

Share to Receptor, ErbB-2

Share to Receptors, Progesterone

Share to Survivin

Share to Taxoids

Source

Identifiers

PMID: 26392111
DOI: 10.1007/s13277-015-4075-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.PMID 26392111Read ↗

New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer CellsSemantic proximity Read ↗

Docetaxel induces cell death through mitotic catastrophe in human breast cancer cellsSemantic proximity Read ↗

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cellsSemantic proximity Read ↗

Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol ResistanceSemantic proximity Read ↗

Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer CellsSemantic proximity Read ↗

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.Semantic proximity Read ↗

Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Telling Cells How to Die: Docetaxel Therapy in Cancer Cell LinesSemantic proximity Read ↗

Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cellsSemantic proximity Read ↗

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell typesSemantic proximity Read ↗

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.Semantic proximity Read ↗

Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.